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The Igh locus undergoes an amazing array of DNA rearrangements and modifications dur-
ing B cell development. During early stages, the variable region gene is constructed from
constituent variable (V ), diversity (D), and joining (J ) segments (VDJ joining). B cells that
successfully express an antibody can be activated, leading to somatic hypermutation (SHM)
focused on the variable region, and class switch recombination (CSR), which substitutes
downstream constant region genes for the originally used Cµ constant region gene. Many
investigators, ourselves included, have sought to understand how these processes specif-
ically target the Igh locus and avoid other loci and potential deleterious consequences of
malignant transformation. Our laboratory has concentrated on a complex regulatory region
(RR) that is located downstream of Cα, the most 3′ of the Igh constant region genes.
The ~40 kb 3′ RR, which is predicted to serve as a downstream major regulator of the Igh
locus, contains two distinct segments: an ~28 kb region comprising four enhancers, and
an adjacent ~12 kb region containing multiple CTCF and Pax5 binding sites. Analysis of
targeted mutations in mice by a number of investigators has concluded that the entire 3′
RR enhancer region is essential for SHM and CSR (but not for VDJ joining) and for high
levels of expression of multiple isotypes. The CTCF/Pax5 binding region is a candidate for
influencing VDJ joining early in B cell development and serving as a potential insulator of
the Igh locus. Components of the 3′ RR are subject to a variety of epigenetic changes
during B cell development, i.e., DNAse I hypersensitivity, histone modifications, and DNA
methylation, in association with transcription factor binding. I propose that these changes
provide a foundation by which regulatory elements in modules of the 3′ RR function by
interacting with each other and with target sequences of the Igh locus.
Keywords: immunoglobulin heavy chain gene locus, enhancers, insulators, CTCF, Pax5, class switch recombination,
somatic hypermutation
DISCOVERY OF 3′ RR ENHANCERS
The Igh locus spans ~3 Mb,beginning near the telomere on murine
chromosome 12 with the component variable (V ), diversity (D),
and joining (J ) segments of the variable region, followed by the
multiple constant region (CH) genes (Figure 1). My laboratory has
been interested in the regulation of the Igh locus’s multiple recom-
bination and mutation processes that generate a diverse antigen-
recognition repertoire. The entire 3′ Igh regulatory region (RR)
(enhancers and insulators) has been shown by others to poten-
tially contribute to regulation of variable region formation (VDJ
joining) (1). Importantly, it is definitively essential for class switch
recombination (CSR) (2), and somatic hypermutation (SHM) (3).
This review focuses on our studies on the structure and epige-
netic regulation of the 3′ RR as it contributes to those antibody
diversification processes.
The first transcriptional enhancer identified in mammalian
cells was the intronic enhancer of the Igh locus (Eµ), positioned
between the 3′-most JH segment and the 5′-most CH region, Cµ
[reviewed in Ref. (6)]. Eµwas found to confer expression upon Igh
genes when transfected into B cells, and was generally considered
to be of critical importance in enabling B cell-specific expression
of the Igh locus.
Not surprisingly, perhaps, Eµ was not the only B cell-specific
enhancer in the Igh locus. When B cell lines that had deleted Eµ
were found to retain the ability to express the Igh gene (7, 8),
the questions of gene regulation of Igh genes became increasingly
provocative. What exactly was Eµ’s role? Was Eµ required to ini-
tiate Igh expression but not to maintain it? Were there additional
enhancers that compensated for the absence of Eµ, and where in
the Igh locus might they be found? Examining a rat cosmid, the
Neuberger group identified a DNA sequence with B cell-specific
enhancer activity that was located ~25 kb downstream of Cα, the
most 3′ of the CH genes (9): this was the first of the 3′ enhancers
to be identified.
This newly identified enhancer was satisfyingly predicted to
account for the aberrant expression of myc in various B cell malig-
nancies when myc was activated as an oncogene via chromosomal
translocation with the Igh locus. The translocation breakpoints
in switch sequences upstream of CH genes divorced the intronic
enhancer from the oncogenic transcription unit, leaving myc
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FIGURE 1 | Schematic representation of mouse (A) and human (B) Igh
gene loci with emphasis on the 3′ RR. The depicted orientation reflects the
centromere (proximal) to telomere (distal) orientation of the genome
sequences. DNase I hypersensitive sites hs3A, hs1.2, hs3B, and hs4 (mouse)
(red line); and hs3, hs1.2, and hs4 (human) are enhancers of the 3′ RR.
(A) Hs1.2 is the center of a palindromic region (double-headed arrow) (see
text). The 3′ RR hs5–8 region (gray hexagon) downstream of hs4 contains
CTCF sites interspersed with Pax5 sites, and has insulator activity (blue line).
Each of the downstream neighboring non-Igh genes, hole (Tmem121), crip1
and 2, and mta-1, has the same transcriptional orientation (demarcated by
purple arrows), which is opposite to that of all the immunoglobulin heavy
chain genes. Arcs indicate examples of physical interactions that occur in B
cells among the elements of the 3′ RR, and between these elements and
regulators of germline transcripts (GT) that are located upstream of switch
sequences associated with each CH gene, or with the expressed VDJ gene.
Transcription factor binding sites for Pax5, NFκB, octamer-binding proteins,
and a G-rich DNA binding protein are present in each of the 3′ RR enhancers
(4) (red line). The CTCF-binding region (blue line) has binding sites for Pax5 and
cohesin in addition to CTCF (5). (B)The human 3′ Igh enhancers and other
features are shown to scale under the scheme of the locus. Numbers
represent the actual location within human chromosome 14 (NT_026437.10).
This figure has been used with permission from its original publication in
Molecular Immunology. Some annotations and modifications have been
added.
apparently under the control of the 3′ enhancer [Ref. (9) and
reviewed by Vincent-Fabert et al. (10)]. A murine homolog of
this enhancer was isolated and named hs1.2 for its two DNAse I
hypersensitive (hs) sites (11).
Once more than one Igh enhancer was known, i.e., hs1.2 and
Eµ, it was natural to ask whether there were additional enhancers.
Potential enhancers were identified by DNase I hypersensitiv-
ity assays that marked DNA sites that were accessible to tran-
scription factors, and enhancer activity was generally analyzed
using transient transfection assays in B cell lines reflecting dif-
ferent stages of B cell development. In a series of experiments
by various investigators, using genomic sequences that were only
then becoming identified, additional DNase I hypersensitive sites
3′ of Cα were detected, primarily using the mouse locus as
a model (12–15). A mouse BAC sequence identified by Roy
Riblet was found to encompass the entire 3′ RR and the nearest
downstream non-Igh genes (AF450245) (16). Similar experiments
identified analogous enhancers of the human Igh locus (17–19),
with the enhancer-containing segment of the human 3′ RR fully
characterized by the Max laboratory (20). Figure 1 shows the
general features of the enhancer-containing segments of the 3′
RR in both mouse and human. A CTCF/Pax5 binding region
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with insulator activity is located within the 3′ RR downstream
of the 3′ RR enhancers (hs5–8), and will be discussed further
below.
STRUCTURAL FEATURES OF THE 3′ RR
ENHANCER-CONTAINING REGIONS
There are noteworthy structural features of the 3′ RR (note that
this region is sometimes referred to as 3′ Eα) [reviewed in Ref.
(21–24) (Figure 1)]. (1) Multiple DNase I HS sites with enhancer
activity are dispersed in relatively large DNA segments (~28 kb in
mouse) – a total of four enhancers in mouse (hs3a, hs1.2, hs3b, and
hs4) and three in humans (hs1.2, hs3, and hs4). (2) In humans,
there are two individual 3′ RRs, one each downstream of Cα1 and
Cα2, respectively. They are quite similar to each other in sequence.
The orientation of hs1.2 with respect to upstream and downstream
sequences is reversed in the two 3′ RRs in human, and also between
rat and mouse 3′ RRs (18). (3) A conserved palindrome feature,
although not its specific sequences, flanks the central enhancer –
hs1.2 (25). In mouse, the palindrome extends in both directions
from hs1.2 to terminate at two virtually identical enhancers, hs3a
and hs3b (26). Compared to mouse, the hs1.2 palindromic region
in humans is shorter (27). Other species also have a conserved
palindrome (28). (4) The hs4 enhancer is located outside and
downstream of the palindrome. (5) Individual 3′ RR enhancers in
a given species, like hs1.2, hs3, and hs4, differ in sequence from each
other (except for the virtually identical hs3a and hs3b in rodents).
(6) There are limited homologies in enhancer sequence between
species (e.g., hs1.2 in human and hs1.2 in mouse) (27).
Other than revealing a conserved palindromic structure, the
regions between the 3′ RR enhancers show virtually no homology
between rodents and humans (27). Nonetheless, other particular
sequence features stand out, as identified through genomic South-
ern analysis and percentage identity (dot-plot) analysis (29). In
mouse (and rat), the “palindromic” sequences that separate hs1.2
from each of the terminal enhancers at the end of the palindrome,
hs3a and hs3b, contain families of direct and inverted repeats
(26) while the human (and chimpanzee) 3′RR revealed several
regions of repetitive switch-like sequences (27). More recently,
the Cogne laboratory specifically sought and identified multiple
switch-gamma 1-like repeats in the mouse and human 3′ RRs that
were situated close to each of the four enhancers, as well as less
distinct although evident, similar sequences in other species, like
rabbit and dog (30). In mouse, the 3′ RR is highly polymorphic (26,
31), showing variations in the lengths of the sequences between
the enhancers and the number of repeats in these regions. The
hs1.2 region in humans is polymorphic, with varying frequency
of alleles in different populations (32). Polymorphic patterns of
human hs1.2, i.e., alleles, are associated with different autoimmune
disorders, such as lupus (33).
In summary, the 3′ RR contains several enhancers located in two
structurally distinctive modules – (1) a palindromic region (mouse
hs3a–hs1.2–hs3b) and (2) a separate structural unit (hs4). Inter-
enhancer regions reveal repetitive, switch-like sequences poten-
tially of functional significance for the Igh locus. Downstream of
the enhancer-containing segment of the 3′ RR is additional DNase
I hypersensitive sites (hs5–8), which contain CTCF and Pax5 sites
and have insulator activity. This hs5–8 region is discussed more
fully later.
TRANSCRIPTIONAL REGULATION OF 3′ RR ENHANCERS
Relatively coincident with these studies on the Igh locus were stud-
ies of genes of the β-globin locus, which, like the Igh genes, are
subject to developmental regulation. Multiple DNase I hypersen-
sitive sites, each with enhancer activity, are located upstream of
the β-globin genes. This enhancer-containing region is referred to
as the locus control region because endogenous deletions here are
found to affect expression of distally situated globin genes. Experi-
mental questions on Igh genes have paralleled experiments carried
out in the β-globin locus and in other loci [recent review in Ref.
(34)]: (1) what are the protein factors that bind to and regulate
these Igh enhancers? Can they account for B cell-specific regu-
lation? (2) Are the different enhancers similar in their function,
their relative “strength” and their activity on the target Igh locus?
How do these enhancers work together? Can these questions be
answered not only for in vitro, cellular conditions but also within
the animal context itself?
Electrophoretic mobility shift assays (EMSA) provided a tool
to identify proteins with the potential to bind enhancers. Using
nuclear extracts, we identified a B cell-specific binding protein with
sites throughout the Igh locus, including hs1.2 (35, 36). Based on
its cellular expression pattern, we predicted that this protein was
B cell-specific activating protein (BSAP), now called Pax5, as orig-
inally identified by the Busslinger laboratory (37); and various
observations were consistent with that prediction (36). Additional
3′ RR binding factors were identified leading to recognition of a
quartet of proteins – Pax5, octamer-binding proteins, NFκB, and
a G-rich DNA binding protein – that worked together on each of
the murine 3′ enhancers (4) (Figure 1).
Our experiments revealed that BSAP/Pax5 bound to each of the
mouse 3′ RR enhancers, where it could act as a repressor or acti-
vator (4). For example, mutational inactivation of a BSAP/Pax5
binding site of hs1.2 resulted in an increase in hs1.2 enhancer
activity upon transfection into B cell lines that expressed endoge-
nous BSAP/Pax5 (36). This finding showed that “BSAP” could be a
repressor of hs1.2. The enhancer activity resulting from mutation
of the BSAP/Pax5 binding site depended on the binding of the
remaining transcription factors (38). A similar outcome applied
not only to BSAP/Pax5 but also to each individual component
of this quartet, as individual mutation of other binding sites each
resulted in an increase in hs1.2 enhancer activity (38). Collectively,
then, this quartet worked in concert to repress hs1.2, while it acti-
vated hs4, revealing that individual 3′ RR enhancers had different
B cell-specific activities (4). Interestingly, human 3′ enhancers do
not have Pax5 binding sites, suggesting that humans and mice have
different modes of 3′ RR regulation. However, it is not known how
or whether the differences in Pax5 binding affect the function of
the 3′ RR in human and mouse. Human hs4 showed binding to
octamer-binding proteins, NFκB, and YY1 under some circum-
stances, and human hs1.2 to octamer-binding proteins and Spi1,
and to NFκB for some of the polymorphic hs1.2 variants (33, 39–
41). Other 3′ enhancer binding proteins have also been identified
(40, 42).
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ADDITIONAL MODULE DOWNSTREAM OF 3′ RR ENHANCERS:
THE CTCF-BINDING REGION OF THE 3′ RR
Had we identified all the regulators of the 3′ RR [reviewed in Ref.
(43)]? Various observations suggested that additional functional
motifs were present beyond hs4. For example, the nearest non-Igh
genes downstream of hs4, i.e., hole (Tmem121), Crip, and mta-1,
each had a transcriptional orientation that was opposite to that
of all of the V, D, J, and CH elements of the Igh locus. This back-
to-back orientation led us to predict that a terminus of the Igh
locus might be located in this segment (16). In fact, we found
additional DNase I hypersensitive sites downstream of hs4, which
included hs5, 6, and 7, and has now been extended to include
a CTCF-binding site, named hs8 (44, 45). Discussions via Sandy
Morse with Victor Lobanenkov introduced us to CTCF as a mam-
malian insulator (46), and we predicted that CTCF sites might be
present in this region. EMSA of 50 overlapping DNA sequences
with recombinant CTCF revealed a CTCF-binding module of the
3′ RR [recently referred to as 3′ CBE, CTCF-binding elements
(47)], and transient transfection assays confirmed functional insu-
lator activity in the absence of any enhancer activity (44). The
CTCF sites are interspersed with Pax5 binding sites within the
hs5–8 region (5).
FUNCTIONAL ANALYSIS OF 3′ RR REGULATORY ELEMENTS
THROUGH TARGETED DELETIONS
3′ RR ENHANCERS
Analysis of the function of the endogenous 3′ RR began with the
description of spontaneous 3′ RR deletion mutants identified in
cell lines. For example, a low-producing variant (LP1.2) of a mouse
plasmacytoma cell line was shown to have sustained a deletion of
the entire 3′ RR (15, 48). This suggested that the 3′ RR supported
high levels of Igh expression in plasma cells. With the develop-
ment of both transgenic (49, 50) and endogenous models, the
3′ RR has been over many years the focus of multiple targeted
deletions [reviewed in Ref. (24)]. Although the efficiency of tar-
geting of this 3′ RR region has been hampered, perhaps because
of its complex structure, there has been gradual, ongoing success.
Deletion of individual enhancers had no significant phenotypic
consequence implying that the remaining elements, each constel-
lation of which is different, can provide 3′ RR function. Deletion
of two or more enhancers gave phenotypic consequences of vary-
ing degrees, e.g., deletion of hs3b and hs4 together eliminated class
switching to all isotypes except for IgG1 (51). Now, there are mice
from which the entire ~28 kb 3′ enhancer region has been deleted
(2), and these have provided a clear demonstration of the potency
of the complete 3′ RR enhancer region. Without 3′ RR enhancers,
mice are able to express only reduced levels of IgM at the plasma
cell stage, they lack class switch recombination to all isotypes (2)
and they are deficient in SHM (3). There is no impairment of
VDJ joining (52). Studies by the Cogne laboratory showed that
3′ RR enhancers hs1.2 and hs4 were transcriptionally active in B
cells, and hs1.2 could be targeted by AID, revealed by detectable
although relatively low levels of SHM (30). These AID-dependent
mutational and recombination processes involving the 3′ RR with
Sµ resulted in deletion of the entire IgCH region and B cell death
(30). This revealed an ongoing competition between generation of
live class switched mutated B cells and dead B cells, termed “locus
suicide” by the authors. In all, these data strongly show that the 3′
RR enhancer region (hs3a–hs4) is critical for CSR and SHM and
functions through synergy among the multiple 3′ RR enhancers.
CTCF/Pax5 BINDING REGION
Similar to the analysis of the 3′ RR enhancers, we used targeted
deletion to examine the effect of the CTCF/Pax5 binding region
of the 3′ RR on Igh expression (53). We were surprised to find that
deletion of the 8 kb hs5–7 region resulted only in a mild pheno-
type. There was an increase in recombination of the most proximal
D gene, DQ52, to JH3, a reduction in contraction between distal
VHJ558 and proximal VH7183 genes, and an ~2-fold increase in
VH7183 gene usage-all suggesting a modest contribution of the
CTCF/Pax5 region of the 3′ RR to steps in VDJ joining. Nonethe-
less, upon targeted deletion of hs5–7, there were essentially normal
levels of Igh recombination for VH formation and CSR,normal lev-
els of Igh expression and allelic exclusion, and B cell development
was unaffected. One possibility to account for these observations
was our finding that two CTCF sites remained downstream of the
seven sites that had been deleted, in the segment called “38” in the
manuscript and now termed hs8. In addition, CTCF sites are asso-
ciated with each of the downstream non-Igh genes. This suggests
that a full deletion of CTCF sites in this region might reveal a more
extensive phenotype.
PHYSICAL INTERACTION OF THE 3′ RR WITH ITS TARGET
SITES IN THE Igh LOCUS
VH promoters and I promoters that drive germline transcription
(GT) for CSR are situated quite far in a linear distance from the 3′
RR; yet it is implied that they all function together through physical
interaction (Figure 1). In fact, our finding of an inversion of the Igh
locus in a variant of the MPC11 plasma cell line that extended from
the VH through to the 3′ RR (54) was indicative of a loop formed
by interactions between DNA sequences at VH and 3′ RR inver-
sion breakpoints (55). Chromosome conformation capture (3C)
technology has been important in documenting interactions that
occur in a cellular context, by fixing these by formaldehyde cross-
linking, cutting away intervening DNA stretches with restriction
enzymes, ligating remaining neighboring fragments, and docu-
menting these interactions by PCR with selected primer pairs.
Using 3C, we sought to confirm the dependence of H chain expres-
sion in plasma cells on an intact 3′ RR (55): indeed, we found that
the 3′ RR interacted with the JH–Eµ region. This interaction took
place even in cells in which Eµ was deleted. Not only was there
interaction between the 3′ RR and its target sequences, but there
was also interaction among component 3′ RR enhancers and insu-
lators, including the CTCF/Pax5 binding unit (hs5–8) (3′ CBE).
Notably, substitution of hs1.2 by the NeoR gene in a variant of
the MPC11 plasma cell line resulted in loss of Igh expression (56)
and abrogation of the 3′ RR loop structure; i.e., looping was essen-
tial for Igh expression. Collectively, these experiments show that
the entire 3′ RR, including enhancers and insulators, works as a
physical unit.
The Kenter laboratory focused on normal spleen cells stimu-
lated to undergo switching for their 3C experiments (57). They
reported that in resting B cells, but not in T cells, the 3′ RR inter-
acted with the VDJ –Eµ region. Upon LPS± IL4 stimulation of
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splenic B cells, they found that specific I/switch regions that drive
GT were brought into the VDJ –3′ RR loop. Splenic B cells from
mice that were unable to carry out GT and CSR as a result of the
combined deletion of the hs3b and hs4 3′ RR enhancers failed to
show these interactions.
Interestingly, mice bearing the combined deletion of hs3a and
hs3b (58) had no defects in GT or CSR, but interactions between
the 3′ RR and I/switch regions that ordinarily were cytokine-
dependent were already at an induced level in the hs3a/hs3b
deleted mouse. Collectively, these data provided support for a
loop interaction model by which H chain expression and CSR
are dependent on physical interaction of the 3′ RR with target Igh
sequences.
Presuming that the CTCF/Pax5 region (3′ CBE) of the 3′ RR
interacts with other Igh-associated CTCF sites, such candidate
CTCF target sites have been defined by colleagues using array
analysis and genome-wide ChIP (59, 60). Moving 3′–5′ upstream
of the 3′ RR, there are no CTCF sites in CH and JH genes until those
detected in the 5′ DH segment (1, 61). The VH region contains
multiple CTCF sites, some associated with specific Pax5 binding
sites, termed PAIR (62). Recent studies showed that the 3′ RR
CTCF/Pax5 binding region interacts with the two DH-associated
CTCF sites (IGCR1), targeted deletion of which showed their crit-
ical role in appropriate regulation of VDJ joining (1). We might,
therefore, predict that the deletion of the complete 3′ RR CTCF-
binding region with which IGCR1 interacts would have a major
influence on VDJ joining.
Genome-wide analyses have been used to identify interactions
between 3′ RR elements, e.g., hs3b and hs8, and the rest of the
Igh locus (47, 63). Studies with 4C (47) have identified Pax5-
dependent interactions in Rag−/− pro-B cells where VH genes are
poised to contract prior to VDJ joining. These 3′ RR interactions
are maintained even when individual regulatory elements, such as
Eµ, IGCR1, and the entire 3′ RR enhancer region from hs3A to
hs4, are deleted. This implies some independent means of inter-
action, perhaps involving retained 3′ RR CTCF-binding sites, or
synergy among regulatory elements that enables continued inter-
actions even when single elements are deleted. Notably, chromatin
interaction analysis by paired-end tag sequencing (ChIA-PET) of
long-range chromatin interactions has revealed interactions of the
3′ RR with transcribed Igh genes in B cells activated by LPS+ IL4
that are not detected in embryonic stem (ES) cells (63), in accord
with developmental differences in 3′ RR interactions.
WHAT PROTEINS SUPPORT LOOP FORMATION INVOLVING
THE 3′ RR?
To tackle this question, we used lentiviral delivery of shRNA
directed against expression of CTCF, Oct-2, and a coactivator
of Oct-2, namely Pou2af1 [i.e., OCAB, OBF-1, BOB1, each of
which, as proteins that bound to the 3′ RR, was a candidate for
loop promotion (64)]. Despite reduced levels of these proteins in
response to shRNA, no alterations in loop formation or Igh expres-
sion were observed in the mouse MPC11 plasmacytoma cell line
we examined. Interestingly, in contrast to our observations, there
was a report that reduction of Pou2af1 expression in the same
plasma cell line using step-wise selection of a cell line containing
two independent shRNA’s led to reduction in Igh expression and
3C interactions (65). Accordingly, we concluded (64) that there
are likely some conditions under which Pou2af1 can facilitate 3C
interactions involving the 3′ RR, among them the possibility that
this approach had selected a variant cell line that was dependent
on Pou2af1. Potentially, under other conditions, 3C interactions
depend on a protein other than Pou2af1, or on synergy involving
more than one protein, or on the low levels of individual proteins
remaining from inefficient knock down.
EPIGENETIC REGULATION OF 3′ RR DURING B CELL
DEVELOPMENT
Over several years, we have worked to know how components
of the 3′ RR are individually regulated, enabling them, in turn,
to act together as a unit in CSR and SHM, and potentially also
for VDJ joining. “Active” DNA segments are generally associated
with DNase I hypersensitivity, specific histone marks, and DNA
demethylation, which will be discussed individually below.
HISTONE MARKS
Non-B cells that were studied had varying profiles of histone acety-
lation of the 3′ RR (66). For example, a macrophage cell line had
active marks of AcH3 and AcH4, while T cells lacked both AcH3
and AcH4. In mouse erythroleukemic (MEL) cells, the CTCF-
binding region, but not 3′ RR enhancers, was associated with
acetylated histones. Therefore, active histone marks of the 3′ RR
were not necessarily B cell-specific. In B cells, modules of the 3′
RR sequentially acquire active histone marks during development
(44). The CTCF-rich region first acquires these marks, followed
progressively 5′ to hs4 and then to the palindromic enhancers.
ChIP experiments of the 3′ RR showed that in pro-B cells, hs5 and
hs6 of the CTCF-binding region were associated with AcH4 and
low levels of AcH3, while hs4 was also associated with AcH4 but not
with AcH3. In pre-B cells, the entire hs4–8 region was associated
with both acetylated marks; and then in B cells, the palindromic
enhancers also acquired these marks. These observations suggest
step-wise activation of different modules of the 3′ RR during B cell
development, raising the possibility that specific combinations of
3′ RR modules, involving palindromic enhancers, hs4, and the
CTCF-binding region, have specific functional contributions.
DNA DEMETHYLATION
Early studies had bluntly monitored DNAse I hypersensitivity and
DNA demethylation in the region now shown to contain the
entire 3′ RR (12), but as the complete 3′ RR structure became
known, a finer analysis was made possible (66). The CTCF-
binding region was generally constitutively demethylated in all
cell types analyzed. In several sources of non-B cells, the 3′ RR’s
palindromic region was demethylated without a corresponding
association with active histone marks. However, in B cells, three
epigenetic marks – DNase I hypersensitivity, active histone marks,
and DNA demethylation – were collectively engaged; and progres-
sive demethylation paralleled acquisition of active histone marks.
Hs4 and downstream CTCF-binding sites were DNase I hypersen-
sitive and demethylated, as assessed by relative sensitivity to the
methylation-sensitive isoschizomers HpaII and MspI, beginning
in pro-B cells and extending throughout B cell development. The
palindromic region became hypersensitive and partially demethy-
lated only later in B cell development. We found upon comparison
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of wild-type with Pax5-deficient pro-B cells in which Pax5 expres-
sion could be reinitiated, that in the absence of Pax5, there was
scattered demethylation of the palindromic region. Re-expression
of Pax5 could promote methylation of the palindromic region.
These findings suggested that Pax5 was a critical factor in over-all
B cell-specific epigenetic regulation of the 3′ RR. In other studies
involving targeted deletion of linker histone H1 genes, we found
that linker histone H1 was also important for the methylation of
hs4–hs8 in wild-type ES cells.
EPIGENETIC REGULATION OF 3′ RR DURING CSR
Despite the critical role of the 3′ RR in CSR (and SHM), there are
no apparent changes in histone marks in the 3′ RR during switch-
ing in cultured cells (44). This implies that the 3′ RR in resting B
cells is already epigenetically poised for its activity for CSR. Instead,
we have observed dynamic changes in Pax5 interaction over time
in response to LPS stimulation (5). In resting B cells, Pax5 bound
hs4 and the 3′ RR was mostly methylated. When GT was at a peak
at ~48 h after commencement of LPS stimulation, Pax5 binding
had shifted from hs4 upstream to hs1.2 and downstream to hs7.
By 72 h, when CSR was essentially complete, Pax5 had resumed its
beginning position at hs4. ChIP analysis of cell sources that were
deficient in GT or in CSR showed differences in these Pax5 bind-
ing patterns, in accord with the notion that shifts in Pax5 binding
reflected mechanisms by which the 3′ RR supported GT and CSR.
We have proposed a model by which mouse 3′ RR enhancers form
a scaffold through which Pax5 can interact. Deletion of any indi-
vidual enhancer leaves residual Pax5 sites in each of the remaining
enhancers and in the CTCF/Pax5 binding region, which allows the
3′ RR to remain functional.
ON THE HORIZON: EXPERIMENTS ON THE 3′ RR
HOW DOES THE 3′ RR FUNCTION?
The 3′ RR enhancer region is critical for GT and CSR, and SHM,
and the CTCF/Pax5 binding region could contribute to VDJ join-
ing. We predict that a scaffold formed by modules of the 3′ RR
supports physical interactions with target sequences required to
accomplish these various activities. With deletions of individual 3′
RR enhancers having little phenotypic consequence, one can ask
how many different structural solutions are there to 3′ RR activ-
ity? Why are there multiple modules? Do the changes in epigenetic
alterations of 3′ RR modules that occur during development indi-
cate specific activities for individual modules? Could the 3′ RR
help target DNA repair proteins involved in SHM or CSR? What
roles does the 3′ RR share with other cis acting sequences that are
critical for SHM, such as those in the light chain loci? What is
distinctive about CSR, which is specific to the Igh locus? What is
the role of the conserved palindrome? How did the 3′ RR evolve?
What are the species-specific aspects of 3′ RR regulation?
Recent experiments on the β-globin LCR have identified hierar-
chical regulation by multiple transcription factors (67). Binding of
individual factors can provide a foundation for subsequent bind-
ing of other factors. Experiments of these types on the 3′ RR could
be equally informative in answering how this region functions.
Indeed, more complete deletion of 3′ RR CTCF-binding sites, and
targeted deletions and mutations in 3′ RR modules would also be
informative. The new CRISPR technology (68) should facilitate
these constructions and provide answers to many questions.
IS THE CTCF/Pax5 BINDING REGION THE TERMINUS OF B
CELL-SPECIFIC REGULATORS OF THE Igh LOCUS?
A persuasive set of experiments says “yes” to the role of the 3′ RR
as a terminus of Igh regulation via chromatin accessible marks.
These experiments have shown that active chromatin marks extend
unilaterally 3′–5′ from the 3′ RR as far as 450 kb when Igh-myc
translocations are assayed in endemic Burkitt lymphoma samples
(69). This supports the identification of the CTCF/Pax5 region
as a functional insulator of the Igh locus. In addition, 4C studies
have implicated hs8 as a 3′ boundary for Igh locus interactions
(47). Yet, as described below, there is a replicative terminus fur-
ther downstream, raising the possibility of additional Igh locus
regulators.
ROLE OF REPLICATIVE TERMINUS DOWNSTREAM OF CTCF/Pax5
REGION
Our experiments in collaboration with the Schildkraut laboratory
identified an origin of an ~500 kb Igh temporal replicative transi-
tion region in MEL (non-B) cells. DNA replication initiates ~45 kb
downstream of the CTCF/Pax5 module of the 3′ RR between crip1
and Tmem121 (Figure 1) and extends progressively 3′–5′ through-
out S phase to replicate the 3′ RR, CH, JH, DH, and most proximal
V regions (70, 71). All VH genes replicate late in S phase. In pre-
B cells, the entire Igh locus replicates early in S phase, indicating
the firing of multiple origins that are ordinarily quiescent in non-B
cells (71). In B cells, a temporal transition region is again apparent,
but origins appear to be closer to or within the 3′ RR, suggesting
that the replication landmark is flexible (72). These data implied
that Igh replication is under B cell-specific developmental control.
In MEL cells, the downstream origin, which is located beyond the
limits of the 3′ RR, may be a terminus for Igh locus regulation. It
is of interest that changes in Igh DNA replication are associated
with changes in nuclear location of the Igh locus (71, 73) but can
be independently regulated (74). In pro- and pre-B cells, the Igh
locus is located away from the nuclear periphery, while in MEL
and ES cells, and in B and plasma cells, the Igh locus is located
at the nuclear periphery. These observations raise the question
of whether there are finer demarcations of nuclear subcompart-
ments generally associated with the Igh locus and the 3′ RR? What
regulates the movement of the locus from one position to another?
IS THE 3′ RR INVOLVED IN INTER-CHROMOSOMAL INTERACTIONS?
The mechanism by which recurrent translocations involving the
Igh locus take place and the role of the 3′ RR are under close
scrutiny (75, 76). Epner and colleagues have reported a role for
the 3′ RR in transvection involving allelic interactions (77). Fur-
ther, our studies have identified a region between hs4 and hs5 that
has a methylation signature indicative of allelic expression (66).
The Skok laboratory has observed allelic interactions in Igh genes,
which are evident during steps of VDJ joining (78). The various
3C technologies and their broader counterparts, as noted in part
above (47, 63), should be very informative about the contribution
of the 3′ RR to genetic domains of interaction.
Frontiers in Immunology | B Cell Biology April 2014 | Volume 5 | Article 163 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Birshtein Epigenetic regulation of Igh 3′ RR
IS THERE A ROLE OF THE 3′ RR AS A SUPER ENHANCER?
Recent genome-wide studies have reported “super enhancers” (79,
80), DNA segments substantially larger than other “enhancer”
regions and identified as having strong binding sites for BRD4,
a member of the bromodomain and extraterminal (BET) sub-
family of human bromodomain proteins, and for the Mediator
complex with which BRD4 interacts. By these criteria, the 3′ RR
was predicted to be a super enhancer in multiple myeloma cells
(79), where it upregulates expression of the myc oncogene to
which it is juxtaposed as a result of a chromosomal transloca-
tion. An inhibitor of BRD4, JQ1, can lead to downregulation of
myc expression in multiple myeloma cells. However, myc appears
to be suppressed by JQ1 regardless of whether it is associated with
Igh sequences through translocation (81), potentially via B cell-
specific enhancers of myc (47, 63). Is the 3′ RR a super enhancer?
Under what circumstances? Does the 3′ RR share features in com-
mon with other “super enhancers”? How might the 3′ RR become
a super enhancer?
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